

Gender: **Male** | Birth year: **1950** | WHO: **1**

Tumor: **Skin - Melanoma** | Lesions: **CNS, Liver, Lymph nodes** | Stage: **IV**

Summary

Clinical Summary

Relevant systemic treatment history	Vemurafenib (5/2022-2023), Ipilimumab (2023)
Relevant other oncological history	Resection (2021)
	Previous primary tumor: Lung carcinoma (diagnosed 5/2020, considered non-active)
Relevant non-oncological history	Pancreatitis

Recent molecular results

WGS of ACTN01029999 (11-May-2023)

Biopsy location	Liver (purity 98%)
Molecular tissue of origin prediction	Melanoma (100%)
Tumor mutational load	High (185)
Microsatellite (in)stability	Stable
HR status	Proficient
Genes with high driver mutation	BRAF
Amplified genes	None
Deleted genes	PTEN
Homozygously disrupted genes	None
Gene fusions	None
Virus detection	None
Potentially actionable events with medium/low driver:	None

IHC results (06-May-2023)

V600e positive (Panel NGS): BRAF

Approved treatments considered eligible

Treatment

Not yet determined

EMC trials that are open and considered eligible (3)

Trial	Cohort	Molecular	Warnings
Test Trial 1	Cohort B	None	Undetermined SOC exhaustion
TEST-1	Cohort A *	BRAF V600E	Undetermined SOC exhaustion
Test Trial 2	Cohort A *	BRAF V600E	None
TEST-2			

* Cohort currently has no slots available

trial kb trials potentially eligible based on molecular results (1)

Event	Trials
PTEN del	Trial 1

Molecular Details

IHC results (06-May-2023) V600e positive (Panel NGS): BRAF

WGS (ACTN01029999T, 11-May-2023)

General

Purity	Sufficient Quality	Predicted tumor origin	TML Status	TMB Status	MS Stability	HR Status	DPYD	UGT1A1
98%	Yes	Melanoma (100%)	High (185)	High (13.7)	Stable	Proficient	*1 HOM (Normal function)	*1 HET (Normal function), *28 HET (Reduced function)

Drivers

Type	Driver	Driver likelihood	Trials in EMC	Trials in trial kb	Best evidence in kb	Resistance in kb
Mutation (Hotspot)	BRAF V600E (4/6 copies)	High	TEST-1, TEST-2		Approved	
Loss	PTEN del, 0 copies	High		Trial 1		

Clinical Details

Clinical Summary

Relevant systemic treatment history	Vemurafenib (5/2022-2023), Ipilimumab (2023)
Relevant other oncological history	Resection (2021)
	Previous primary tumor: Lung carcinoma (diagnosed 5/2020, considered non-active)
Relevant non-oncological history	Pancreatitis

Patient current details (06-May-2023)

Unresolved toxicities grade => 2	Fatigue (2)
Cancer-related complications	Ascites
Known allergies	Wasps (Environment)
Recent surgeries	16-Apr-2023

Tumor details (06-May-2023)

Measurable disease	Yes
CNS lesion status	Present CNS lesions (active)
Brain lesion status	No known brain lesions

Laboratory results

			16-Apr-2023	26-Apr-2023	06-May-2023
Liver function	Total bilirubin				
	ASAT	(< 33 U/L)			36 U/L
	ALAT				
	ALP				
	Albumin				
Kidney function	Creatinine				
	CKD-EPI eGFR	(> 100 mL/min)	> 100 mL/min		
Other	Hemoglobin	(6.5 - 9.5 mmol/L)			5.5 mmol/L
	Thrombocytes	(155 - 350 10^9/L)	155 10^9/L	151 10^9/L	150 10^9/L
	LDH	(< 245 U/L)		240 U/L	
Tumor markers	CA 15.3				
	CA 125				
	CA 19.9				
	CEA				
	PSA				

Medication details

Medication	Categories	Administration route	Start date	Stop date	Status	Dosage	Frequency
Ibuprofen	NSAIDs		16-Apr-2023	31-May-2023	Active	750 - 1000 mg	1 / day

Blood transfusions

Product	Date
Thrombocyte concentrate	01-May-2023

Trial Matching Summary

EMC trials and cohorts that meet molecular requirements and may be eligible, but are closed (0)

None

EMC trials and cohorts that are open but considered ineligible (1)

Trial	Cohort	Ineligibility reasons
Test Trial 2 TEST-2	Cohort B	Vemurafenib treatment